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Direct to Consumer (DTC) genetic testing is a popular way of learning about 
one’s ancestry, genetic health risks, and traits. Common DTC testing companies include 
23andMe, Ancestry, and Prometheus. This field continues to expand and deepen as 
more companies arise proclaiming genetic tests for a myriad of matters. Unfortunately, 
most individuals that take these tests do not fully understand genetics, relative risk, or 
the regulation and limits of these tests. For individuals that do not have a biology 
background, terms like carrier, genetic risk, and SNPs are foreign terms. This study 
analyzes how Ball State college students perceive genetic testing, their experiences 
with genetic testing, and common barriers to being tested.  
The study found that the main benefits for testing among both tested and 
untested groups were ancestry and traits. Concerns about results, privacy, and cost 
were common barriers to testing. Both groups had medium confidence in quality and 
accuracy of the results and believed that DTC genetic testing was somewhat expensive. 
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Process Analysis Statement 
 I have had an avid interest in genetics ever since my 8th-grade science teacher 
brought up how genetics influences the health of individuals and populations. Over time, 
my interest in genetics grew and diversified into how it influences medicine and public 
health. A few years back I bought a 23andMe Ancestry and Health test and have been 
fascinated by the results ever since. I was riveted with finding out how they determined 
these traits and ancestry from a tube full of saliva. I was particularly interested in the 
things the test got wrong, such as insisting I did not actually have dimples.   
 I wanted to foster this same avid interest in my thesis. I chose to do a survey to 
gain more experience in public health research. In prior research conducted, I had 
performed interviews and analyzed the data from that. Using a survey allowed me to 
reach more people and gain a new research perspective. Once the survey was 
completed, I gained IRB approval and began to distribute the survey. When the survey 
collection period was completed, I analyzed the data. 
 The target audience of this thesis was anyone curious about direct to consumer 
genetic testing. The field itself is still fairly new and is constantly expanding. I wanted to 
begin with a short history of genetics and genetic testing to show how far the field had 
come in such a short time. Following this history, I focused on how genetic testing 
actually works, concerns and regulation of the field, common companies, and why 
college students were selected for this study.  
The biggest lesson I learned from this thesis was determination. At all turns it 
seemed like the process was against me. Between wisdom tooth removal, demanding 
classes, an international trip, a global pandemic, and more, there were plenty of 
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distractions and hurdles to cross. IRB approval, although I had completed the process 
for prior research, is always a beast. Learning a new survey program and how-to best 
format a survey and distribute it was a challenge. Despite these and many other 
personal and academic challenges, I persevered to complete this thesis to the best of 
my ability. This thesis serves as a reminder that although it is impossible to know what 
obstacles will arise to defy the plans we painstakingly lay, a bit of determination, grit, 





 Unraveling the mystery of genetics is a constantly mounting undertaking. Often, it 
seems that as more is unearthed about genetics, new mysteries float to the surface. 
The idea that people can learn about their genetic ancestry, health risk, and traits from a 
tube of spit would seem revolutionary when deoxyribonucleic acid (D.N.A.) was first 
discovered. Now, that same tube of spit can be used to discover genetic variants 
between individuals and use them to give customers insights about themselves. This 
progression is through Direct to Consumer (DTC) genetic testing. Common DTC testing 
companies include 23andMe, Ancestry, and Prometheus. DTC genetic testing is an 
emerging field, and thus its regulation, significance, utility, and accuracy are much 
debated.  
 This paper will cover the history of genetic testing, how DTC genetic testing 
works, current trends, existing DTC companies, regulation, and the perceptions of Ball 
State college students to DTC genetic testing.  
Genetic Testing History 
In 2017, it is estimated that as many as 12 million Americans used DTC genetic 
testing (Huml, 2019). How did we reach this point? The field of genetics has continued 
to flourish after gaining its roots in 1859 when Charles Darwin published his 
controversial On the Origin of Species detailing the idea of Natural Selection. Six years 
later, the field grew further when Gregor Mendel used pea plants in experiments that 
upheld Darwin’s findings. Mendel found that inheritance of traits occurred through the 
transmission of discrete units. These discrete units may appear in the offspring as 
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blended traits or like either parent plant. These ideas helped paint a mechanism by 
which Darwin’s ideas about Natural Selection may work (NIH, 2015). 
In 1871, Friedrich Miescher discovers “nuclein” in the nucleus of cells (Your 
Genome, 2016). Cell division was revolutionized in 1879 by the discovery of mitosis, the 
cell division of a parent cell that results in two genetically identical daughter cells, and 
by Walter Flemming while studying the effect of cell division on the behavior of 
chromosomes (NIH, 2015). The Chromosome Theory of Heredity was the next big 
breakthrough in 1904 by Walter Sutton and Theodor Boveri. They discovered that one 
of each pair of chromosomes was inherited from each parent. These matched pairs 
explain the discrete units that Mendel discovered with his pea plants almost 40 years 
earlier (Your Genome, 2016). 
 The word gene is used by Wilhelm Johannsen first in 1909. In 1911, genes are 
shown to be carried by chromosomes and linkage of genes is discovered by Thomas 
Hunt Morgan in a fruit fly animal model. The conventional thought at the time that 
proteins could ‘transform’ cell properties was disproven in 1944 by Oswald Avery, Colin 
MacLeod, and Maclyn McCarty. Instead, it was DNA, which Miescher had originally 
called nuclein (NIH, 2015). Erwin Chargaff was the next in the line of discovery when in 
1950 he created Chargaff’s rules on the pairing of the DNA bases. The findings 
suggested that Adenine (A) always pairs with Thymine (T). Similarly, Guanine (G) 
always pairs with Cytosine (C). The ideas of Avery, MacLeod, and McCarty were further 
expanded upon in 1952 with the Hershey-Chase experiments, performed by Alfred 
Hershey and Martha Chase. They showed that the true carrier of genetic information 
was DNA, not protein (Your Genome, 2016).  
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 DNA would be further revolutionized in 1953 when James Watson and Francis 
Crick discover DNA’s structure was a double helix using data collected by Rosalind 
Franklin (Your Genome, 2016). In 1958, more detail is discovered about DNA when 
Franklin Stahl and Matthew Meselson find that DNA replicates by the semiconservative 
model. Previously, there were three models that replication was thought to belong to. 
The popular opinion was that DNA was replicated using a conserved model. The new 
strands of DNA would be replicated off of the parent strands of DNA. The new strands 
would ligate together, and the parent strands would relegate together. In 
semiconservative replication, the new strands are also copied off of the parent DNA 
strands. However, the resulting DNA molecules are created from one new and one 
parent strand of DNA. In Dispersive replication, the entire DNA chain breaks down, is 
replicated and randomly recombines to form two new DNA molecules (NIH, 2015).  
 The idea of genetic testing comes into focus in 1959 when the cause of Down 
syndrome is found by Jerome Lejeune and his lab. They detected that having 
chromosome 21 three times vs. the usual 2 led to Down Syndrome. Two years later, in 
1961, Robert Gunthrie creates a test to detect phenylketonuria (PKU) in newborns. This 
disease prevents afflicted individuals from metabolizing phenylalanine. The amino acid 
can then build up in the body and cause severe symptoms if not treated (NIH, 2015). 
Understanding how amino acids affect the body was further understood in 1966. The 
Genetic code was cracked by Marshall Nirenberg and his lab. This enabled scientists to 
better understand which codons (sets of three DNA bases) coded for which amino acids 
when the DNA was used to create proteins (Your Genome, 2016).  
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 The field of cytogenetics and molecular diagnostics then emerged, in 1959 and 
1976 respectively (Botkin, 2015). These brought with them the discovery of restriction 
enzymes (1968), recombinant DNA (1972), and the cloning of the first animal gene 
(1973). In 1975, DNA sequencing was developed by two different groups: Frederick 
Sanger, and colleagues Alan Maxam and Water Gilbert. In 1976, Genentech was 
formed. This was the first company to specialize in genetic engineering. They would 
again make a major impact when they market human insulin in 1982. This was the first 
drug marketed using recombinant DNA (NIH, 2015). The field continued to improve and 
in the year 1983 the invention of polymerase chain reaction (PCR) technique was 
developed by Dr. Kary Mullis. This technique allowed researchers to amplify DNA, or 
create multiple copies of DNA from a single copy in a lab setting (Your Genome, 2016). 
Also in 1983, the lethal autosomal dominant disorder Huntington’s disease, became the 
first disease to have its gene mapped (NIH, 2015). 
 In 1990, a massive undertaking in the field of genetics began. The Human 
Genome project began with the idea that within 15 years they would sequence the 
entire human genome. The human genome contains 3.2 billion bases. Around this time, 
many plants (such as tomatoes), animals (such as mice), and bacterium (E. coli) were 
also being sequenced. Just before the turn of the century in 1999, the Human Genome 
Project succeeds in sequencing its first chromosome, Chromosome 22. Chromosome 
22 was selected first due to its small size and some prior research already existed for it 
(NIH, 2015). In 2003, the Human Genome Project finishes 2 years early. They estimate 
their accuracy to be 99.99% accurate. They also estimate that humans are made up of 
between 20,000 and 25,000 genes (Your Genome, 2016).  
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 The next advancements centered around completing more sequencings of 
plants, animals, and bacterium, creating better DNA sequencing technology, and 
launching projects with the goal to sequence large populations (Your Genome, 2016).  
How does DTC Genetic Testing work?  
For individuals that do not have a biology background, terms like carrier, genetic 
risk, and SNPs are foreign terms. SNPs, or single nucleotide polymorphisms, are one of 
the most common genetic variations and act as biological markers (Roberts, 2017). In 
certain locations in the genome, SNPs are present. In these locations, the A, T, C, or G 
nucleotide can differ between people. One individual may have a C and another may 
have an A in that same location. The human genome is estimated to have about 10 
million SNPs. SNPs are important to genetic research, including genome-wide 
association studies and in tracking ancestry (Genetics Generation, 2015).  
There are several types of genetic tests available. The main difference is what 
the test is looking for. For example, Single-gene tests search for a mutation in a specific 
gene, such as in sickle cell disease. These are usually ordered by a healthcare 
professional when a specific mutation is suspected. Direct to consumer genetic testing 
usually falls under exome or genome sequencing. Exome sequencing test looks at all of 
the genes present in an individual’s DNA. A genome sequencing test looks at all of the 
genes and non-gene DNA present in an individual (CDC, 2020).  
Many DTC genetic testing companies use DNA found in saliva from mouth cells 
(23andMe, 2020). AncestryDNA uses “microarray-based autosomal DNA testing, which 
surveys a person’s entire genome at over 700,000 locations, all with a simple saliva 
sample.” Autosomal DNA is DNA from the 22 chromosome pairs, not the sex 
 
8 
chromosomes X and Y. Microarray-based tests look at gene expression in the genome 
(Ancestry, 2020). 23andMe genotypes DNA and then analyzes it (23andMe, 2020).  
Concerns about DTC Testing  
 Concerns about DTC genetic testing are rampant among geneticists, healthcare 
professionals, and researchers. Major concerns are lack of knowledge and counseling 
of participants, clinician understanding, privacy, discrimination, lack of regulation, and 
questionable clinical accuracy and validity. Addressing these concerns and taking steps 
to improve is critical to enjoying the positives of genetic testing.  
 When a participant finds out that they are at an increased risk of a disease or are 
a carrier, fear is a common first emotion. What constitutes increased risk? Increased 
risk is when an individual has a variant of a gene linked to an increased incidence of 
developing a certain disease or disorder. This increased risk may be relatively small, or 
major. Two well-known mutations are found in the BRCA1 and BRCA2 genes that can 
lead to an increased risk of developing breast and ovarian cancers. By the time she is 
70, a woman with one of these mutations is estimated to have a 50 to 85% chance of 
developing breast cancer over her lifetime. This is a significant increased risk from the 
average population without this mutation. Clinically, knowing that someone has these 
mutations can be beneficial in knowing to increase cancer screenings and to consider 
clinical interventions such as a mastectomy (MSKCC, 2020). Other risks may be an 
increase of only a few percent over the general population. Thus, the concerns of both 
of these risks are very different (Botkin, 2015).  
What does carrier status mean? Carriers carry one allele of a gene that when two 
alleles are present causes a recessive disorder. One well known example is in cystic 
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fibrosis. If two carriers of cystic fibrosis had a child, the child would have a 25% chance 
of having two recessive alleles and cystic fibrosis. Understanding carrier status is 
important to reproductive planning and the prevention of these recessive disorders. 
However, not all companies test for the same variants that cause disease. 23andMe 
tests for 29 variants in the CFTR gene that causes cystic fibrosis. The company states 
that participants “may still have up to a 1 in 230 chance of carrying a variant not covered 
by this test.” If someone has a variant not tested by 23andMe, they may believe they 
are not a carrier and be lulled by a false sense of security about their carrier status 
(23andMe, 2020).  
Further concern is that most individuals do not seek out health care 
professionals, such as genetic counselors or their primary care physician, to interpret 
their results (Roberts, 2017). Many primary care physicians are not comfortable 
addressing DTC genetic testing results with their patients either, which could lead to a 
larger strain on genetic counselors, greater patient anxieties and mistrusts, and a 
continuing misunderstanding of DTC genetic testing results (Powell, 2011). This lack of 
communication and understanding between health care professionals and patients is a 
major concern. For individuals that discover alarming results or misinterpret results, 
their psychological well-being may suffer. This may be presented as anxiety, depression 
and/or anger over their results (Genetics Generation, 2015). 
Privacy, discrimination, and regulation are growing concerns as well. These tests 
are available worldwide and country regulations differ. Addressing this issue would 
require collaboration on an international scale and is a daunting task to undertake. 
Often genetic and personal information are stored in other countries. This data can also 
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be used to identify relatives of the participant. Emerging research shows that even in 
anonymized datasets, the reidentification of the study participants is not impossible 
(Phillips, 2016). As genetic technologies continue to improve, this will likely become an 
even bigger problem (Niemiec, 2016). 23andMe stated in 2015 that law enforcement 
had requested for their help in providing participant data to find suspects (Phillips, 
2016).  
Criminals have already been identified using DTC genetic testing. The online 
database proves a place for individuals to upload raw DNA files they received when 
participating in DTC genetic testing companies like 23andMe and Ancestry. One of the 
investigators of the Golden State Killer cold case, Detective Paul Holes, used DNA from 
the serial killer from a crime scene to create a profile on GEDmatch and matched with a 
distant relative of the Golden State Killer. Over time, Detective Holes created a family 
tree and found the Golden State Killer and his distant relative shared a great-great-
great-grandparent. This information was later used to find and arrest the Golden State 
Killer, Joseph James DeAngelo in April of 2018. Other cold cases have since been 
solved using this or a similar method. Although solving these cases and bringing 
criminals to justice is important, the capture of the Golden State Killer highlights the 
potential privacy ramifications of DTC genetic testing (Jeong, 2018). 
It is currently unknown how accurate and consistent DTC genetic testing 
companies are. However, one study used several sets of identical twins to compare the 
ancestry results between two genetically identical individuals at the same company and 
between two companies. They found consistency between 94.5 and 99.2% when 
looking at ancestry results at the same company. However, results were not near as 
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consistent between companies. This result dropped to between 52.7 and 84.1%. This 
drop highlights the inconsistency in DTC genetic testing when looking at variants tested 
and the data sets of SNPs used as references to compare ancestry results to at each 
company (Huml, 2019). Lack of regulation is further discussed in a later section.  
Direct-to-Consumer Companies 
 There are many different DTC companies worldwide. One study analyzed 246 
companies and found that 30% of them looked at ancestry, 36% and 34% looked at 
non-legal and legal paternity respectively, and 11% offered carrier testing. Two major 
companies that provide these DTC services are Ancestry DNA and 23andMe (Phillips, 
2016). AncestryDNA began as part of a genealogy company in 2012.These tests looked 
at autosomal DNA to determine ancestry and ethnicity. Years later they would launch 
their health component, AncestryHealth. Today, AncestryDNA boasts over 16 million 
people tested, a revenue of over a billion, and over 30 international markets (Ancestry, 
2020). 
  In 2006, 23andMe was established by Anne Wojcicki. The company offers 
ancestry, trait, and health services. In 2017, 23andMe was estimated to be worth over a 
billion dollars and has published over 80 scientific articles. They are the only DTC 
genetic testing company that the FDA approves for validity clinically and scientifically. 
This was not always the case however, as 23andMe ran into problems in 2013 for not 
letting the FDA approve the ability to let customers know about any potential health risk. 
However, in February 2015, the first FDA approved test emerged for the rare disorder of 





In the U.S., genetic tests are regulated by two main federal agencies: the 
Centers for Medicare and Medicaid Services (CMS) and the Food and Drug 
Administration (FDA). These genetic tests are assessed based on their validity 
analytically and clinically, as well as their clinical utility. In other words, can the test 
reliably and correctly predict the genetic variant, does the genetic variant have an 
impact on disease risk, and can the test result help improve clinical outcomes. The CMS 
regulates the analytical validity, but the clinical validity and utility is difficult to address. 
The FDA is taking steps to address the public health threat caused by unregulated DTC 
genetic tests and to address this gap in regulation (NIH, 2019). 
The FDA does not review certain DTC genetic test categories that relate to “non-
medical, general wellness, or low-risk medical purposes.” For example, the FDA does 
not review tests for genetic ancestry or general wellness tests considered low risk. 
Carrier screening tests are required to follow specific regulations, but they are not 
reviewed pre-market by the FDA. Tests for cancer predisposition, pharmacogenetics, 
and genetic health risk require FDA approval in some form. The FDA cautions that 
companies may test for different variants of the same disorder. Thus, a DTC test may 
miss variants that would indicate the condition that a different company would pick up 
on. The FDA recommends meeting with a qualified health provider, such as a genetic 
counselor, to help DTC genetic test customers better understand their results (FDA, 
2019).  
 As genetic testing continues to expand, researchers have several suggestions for 
increasing and improving regulation. Regulation needs to focus on increasing 
 
13 
transparency and creating standards that are consistent throughout the entire industry. 
Additionally, customers need better access to pertinent information such as “how to 
understand risks, benefits, and limitations of genetic testing and DTC services,” 
(Phillips, 2016). Currently 23andMe is the only DTC genetic testing service that meets 
validity standards by the FDA both clinically and scientifically (23andMe, 2020). As the 
field continues to grow, more companies will need to adopt these same standards.  
College Student’s Perceptions  
 College students were chosen due to convenience and to understand how 
undergraduate students at Ball State University viewed Direct to Consumer Genetic Testing. 
Methods 
Participants were recruited to take the online Qualtrics survey through flyers 
posted around Ball State’s campus and emails through campus organizations, the 
Biology Advising center, and through the Honors College. This enabled the survey to 
reach a wide variety of majors and age groups. The survey distribution occurred 
between February 27th to April 19th, 2020. Survey responses were used if the students 
agreed to the comprehensive consent, met the inclusion criteria, and finished over 90% 
of the survey. To meet the inclusion criteria, participants had to be over the age of 18, 
undergraduate students at Ball State University, have access to the survey, and be able 
to read at a high school reading level. The survey respondents were kept anonymous 
and no personally identifiable information was collected from participants.  
The data from the surveys were analyzed to see how responses differ based on 
different demographic criteria, student major, age, years of college completed and if 
they had undergone DTC genetic testing to see if these variables influence perception. 
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Self-perceptions and self-rated understanding of DTC testing were compared. Barriers 
and concerns regarding genetic testing were analyzed to understand common reasons 
students do or do not undergo testing and how this compares to their perceptions. 
Common perceived benefits and cons of DTC genetic testing were also analyzed.  
Results 
The study population was found to be overwhelmingly white females with 
average to above-average health. The age, total family income, and religion varied 
(Table 1). The majority of the students were seniors (53.5%). About half of the tested 
population had major in a science field, but only 37.1% had a major related to health. 
The majority of study subjects had a major in Communication, Health and Nutrition, or 
STEM. The other academic years and majors were about equal (Table 2).  
 Table 3 shows the reported Genetics background. Most participants (37.1%) 
reported an average perceived knowledge of genetics. Knowledge about genetic testing 
was reported by 96.6% of participants, with only 4 out of 116 participants reporting no 
knowledge of genetic testing. The perceived knowledge of DTC genetic testing was 
reported as fair and average in participants (30.2% and 40.5%). Participants obtained 
this knowledge through mass media (68.1%), classes (50.9%), and parents (26.7%). 
Most participants did not perceive DTC genetic testing as useful (Table 3).  
Biology classes taken by participants were also analyzed. High school biology 
was taken by 88.8% and college-level introductory biology by 58.6%. About 20% of 
participants had taken a more advanced biology class such as microbiology, genetics, 
and cell biology. Upper-level genetics courses were taken by 16.4% of the study 
participants (Table 3).   
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Of the 116 participants, 13 (11.2%) had taken a DTC genetic test. The main DTC 
tests taken were Ancestry (69.2%) and 23andMe (30.8%). Most participants stated they 
either already had or would discuss their results with a Genetic Counselor or physician if 
they found concerning results. All tested participants experienced either no regret 
(69.2%) or little regret (30.8%) at being tested (Table 4).  
 About half of tested participants (53.8%) believed that the testing materials 
provided by the company were adequate to answer any questions they had about 
testing and their results. Only 1 participant (7.7%) learned something from the test 
about their health they did not previously know. Most participants (46.2%) expressed 
disappointment that their results did not tell them more information. The same 
percentage viewed genetic testing as beneficial overall (Table 4).  
 Table 5 compared the considerations taken into account and barriers of DTC 
genetic testing between those that had not taken a test and those that had. Most 
participants that had been tested considered genetic ancestry, genetic traits, family 
interest, interest in genetics, and the fun associated with testing. Of those that have not 
been tested, interest was primarily expressed in disease risk, genetic ancestry, carrier 
status, genetic traits, and an interest in genetics. Barriers to testing for those that were 
tested were primarily about cost, validity/usefulness of the test, and concerns over 
privacy. Untested barriers were primarily about cost, privacy concerns, and worry over 
what results might show. In both the untested and tested participants, medium 
confidence was reported in both the quality and accuracy of the results. Genetic testing 





















 DTC genetic testing is a personal decision with many considerations and potential 
barriers. For the 13 participants that had undergone DTC genetic testing, the companies used 
were primarily Ancestry and 23andMe. Participants primarily wanted to take the test to learn 
about their ancestry, traits, and for fun. Those that were untested cared more about certain 
disease risk, ancestry, carrier status, and traits. Those that had already taken a test were more 
concerned about the “fun” categories of genetic testing. These areas likely will not lead to health 
problems. Additionally, they had likely already been exposed to their genetic health reports if 
their test included them. The novelty may have worn off. Finally, the sample size is small and 
may not be truly representative of the population. The data suggests that the main 
considerations for genetic testing between both populations are ancestry and traits.  
 Barriers followed a similar trend. Those that had been tested were not worried about the 
results, likely because they had already taken the test and were not worried by them. More of 
the tested population did not think the results were valid (23.1% vs. 9.7%). However, the 
percentages were more similar between the groups for usefulness. Privacy was a higher 
concern in those that had not been tested. Their testing status may mean they do not place as 
much weight on the testing categories because they had already had the test. Both groups 
agreed that they had medium confidence in the quality and accuracy of the results and believe 
DTC genetic testing is somewhat expensive. The data suggests that concerns about results, 
privacy, and cost may be the main barriers to testing in this population.  
 Most participants had a perceived average understanding of biology and DTC genetic 
testing. Knowledge primarily came from the mass media and classes. High school and 
introductory biology courses were both taken by over half of the population. About 20% had 
taken at least one upper-level biology classes. These classes would influence perceived 
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knowledge of DTC genetic testing, as students would learn more about genetics. This would 
increase their perceived knowledge of both genetics and DTC genetic testing.  
 Of the 13 individuals tested that had participated, 53.8% had already or would discuss 
their results with a genetic counselor or physician. Very little regret was expressed over being 
tested. Predominantly, participants were satisfied with the educational materials provided but 
were disappointed they did not learn more from their results. Overall, 46.2% believed that 
genetic testing was a beneficial experience. 
 Overall, these results may be skewed due to a small sample size, especially for the 
tested population. The majority of participants were white (90.5%), female (79.3%), Catholic or 
Christian (54.3%), and seniors (53.4%). Additionally, the survey was distributed during a global 
pandemic, which may increase health anxieties. Future studies should be aimed at a larger and 
more diverse population not in a global pandemic. Other studies may look at considerations and 
barriers to DTC genetic testing before the tested populations seeing their results to see if 
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Appendix 1: Questionnaire 
Start of Block: Informed Consent 
 
Q1 Study Title Perceptions of College Students on Direct-to-Consumer Genetic 
TestingIRBNet# 1525218-1  
 
Study Purpose and Rationale 
The purpose of this study is to determine the perceptions of Ball State University 
undergraduate students to Direct-to-Consumer (DTC) genetic testing. The information 
collected will be analyzed to see the results of different majors, genders, and class year 
have on perceptions. Additional analysis will determine the interests, concerns, and 
barriers that go into the decision of testing. Perceived understanding of the results is 
also analyzed.   
Inclusion/Exclusion Criteria 
For eligibility in this study, you must be 18+ and an undergraduate student at Ball 
State University. You must also have access to a computer to take the survey and be 
able to read at a high school reading level.  
Participation Procedures and Duration 
The survey begins with demographic information and then asks questions about 
experiences and perceptions about genetic testing. The survey will last approximately 
15-20 minutes.  
Data Confidentiality and Anonymity 
All data collected is anonymous. The survey is collected online and no personal 
identifying information will be collected.  
Storage of Data and Data Retention Period 
Data will be stored on a password protected computer and will be kept for 4 years. 
Data will not contain any identifiable information. 
Risks or Discomforts 
The only anticipated risk attached to this study is that the study asks questions about 
personal feelings about genetic testing that may make you uncomfortable to answer. 
You are not required to answer any question that makes you uncomfortable and you are 
able to quit the study at any time without penalty. Ball State’s Counseling Center can be 
found in Lucina Hall, Room 320 in Muncie, IN 47306 or can be contacted at 765-285-
1726 or counselctr@bsu.edu to address any discomfort that arises from the study.  
Benefits 
There are no direct benefits to the survey participant for participating in this study. 
The results of this study will show the perceptions of Ball State University 
undergraduate students towards third-party genetic testing. The results will show how 
different student experiences influence their views on third-party genetic testing. This 
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research may also show gaps in the understanding of genetic testing and the need for 
greater science literacy among BSU undergraduate students.   
Voluntary Participation 
Your participation in this study is completely voluntary and you are free to withdraw 
your permission at any time for any reason without penalty or prejudice from the 
investigator. Please feel free to email any questions to the investigator before signing 
this form and at any time during the study.   
IRB’s Contact Information 
For one’s rights as a research subject, you may contact the following: Office of 
Research Integrity, located at Ball State University, Muncie, IN 47306. They can be 
reached at 765-285-5088 or ORIHELP@bsu.edu.  
Researcher Contact Information 
Feel free to contact the individuals that are conducting this study with any questions 
or concerns. Contact information is listed below: 
Principal Investigator: Taylor Johnson (tpjohnson2@bsu.edu) 
Faculty Supervisor: Dr. Jagdish Khubchandani (jkhubchandan@bsu.edu, 765-285-
8345).  
Consent 
By selecting "I consent, begin the study," below, you agree that you are at least 18 
years old, a Ball State undergraduate student, and willingly consent to participate in this 
study. If you do not consent to participate in this study, please select "I do not consent, I 
do not wish to participate," and exit your internet browser. 
o I consent, begin the study 
o I do not consent, I do not wish to participate  
Skip To: End of Survey If Study Title Perceptions of College Students on Direct-to-Consumer Genetic 
Testing IRBNet# 1525218... = I do not consent, I do not wish to participate 
End of Block: Informed Consent 
 
Start of Block: Default Question Block 
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Q2 What is your gender? 
o Male  
o Female  
o Other 
 
Q3 What is your age? 
o 18  
o 19  
o 20  
o 21  
o 22  
o 23  
o 24  
o 25+  
 
Q4 What is your race? 
o White  
o Black or African American  
o American Indian or Alaska Native  
o Asian  
o Native Hawaiian or Pacific Islander  
o Multiracial  
o Other  
 
Q5 Which of the following describes your ethnicity? 
o Hispanic/ Latino  




Q6 What is your total family income before taxes? 
o Less than $29,999  
o $30,000-49,999   
o $50,000-69,999  
o $70,000-99,999  
o $100,000-$119,999  
o More than $120,000  
 
Q7 What is your religion? 
o Catholic/Christian  
o Judaism  
o Islam  
o Buddhism  
o Hinduism 
o Non-religious / Atheist  
o Other: ________________ 
 
Q8 What academic year are you? 
o Freshman  
o Sophomore  
o Junior  
o Senior  
 
Q9 Is your major in a science-related field? 
o Yes  
o No   
 
Q10 Is your major in a health-related field? 
o Yes  




Q11 Which is the closest to your major? 
o Teaching  
o Business  
o Communications  
o Architecture  
o Health and Nutrition 
o Social Sciences  
o Humanities  
o Art and Fine Arts  
o Nursing 
o Biology  
o Chemistry  
o Physics  
o Math and Statistics  
 
Q12 How do you perceive your knowledge of genetics? 
o Poor  
o Fair  
o Average  
o Above Average  




Q13 Which of the following Biology classes have you taken? 
▢ High school biology  
▢ BIO 100 (Biology for a Modern Society)  
▢ BIO 102 (Biology Concepts for Teachers)  
▢ BIO 111 or 112 (General Biology)  
▢ BIO 113 (Microbiology for Health Sciences) 
▢ BIO 214 (Genetics)  
▢ BIO 215 (Cell Biology)  
▢ BIO 313 (Microbiology)  
▢ BIO 448 (Biometry)  
▢ BIO 452 (Advanced Genetics)  
▢ BIO 453 (Human Genetics)  
▢ BIO 454 (Genomes)  
▢ BIO 457 (Molecular Biology)  
 
Q14 How would you report your health? 
o Poor  
o Fair   
o Average  
o Above average  
o Excellent  
 
Q15 Have you heard of or know about genetic testing? 
o Yes  
o No  
 
Skip To: Q17 If Have you heard of or know about genetic testing? = No 
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Q16 How did you find out about genetic testing? 
▢ Parents  
▢ Siblings  
▢ Extended relatives 
▢ Friends  
▢ Healthcare provider  
▢ Mass media  
▢ Classes 
▢ Other:  ________________ 
 
Q17 Has anyone in your family had genetic testing? 
o Yes  
o No 
 
Q18 How do you perceive your knowledge of direct-to-consumer (DTC) genetic testing 
(i.e. 23andMe, Ancestry, etc.)?  
o Poor  
o Fair   
o Average  
o Above Average  




Q19 Please rate how useful you believe genetic testing is for someone your age. 
o 0  
o 1  
o 2  
o 3  
o 4   
o 5   
o 6  
o 7  
o 8  
o 9  
o 10  
 
Q20 Have you taken a direct-to-consumer (DTC) genetic test? 
o Yes  
o No   
 
Skip To: Q25 If Have you taken a direct-to-consumer (DTC) genetic test? = No 
 
Q21 Which brand's DTC test(s) did you take? 
▢ 23andMe (Ancestry)  
▢ 23andMe (Health Traits)  
▢ Ancestry  
▢ FamilyTreeDNA  
▢ Promethease  




Q22 Which of the following reflect your experience with genetic testing? Please select 
all that apply. 
▢ The educational materials provided by the company about genetic testing were 
adequate  
▢ Having personal genomic testing made me feel like I have more control over my 
health  
▢ I learned something to improve my health from my genetic testing that I didn't 
know before   
▢ The information I received has influenced how I will manage my health in the 
future  
▢ What I learned about my genetics can help reduce my chances of developing a 
disease  
▢ Genetic testing was a beneficial experience  
▢ I am disappointed that my results did not tell me more information  
▢ Other: ________________ 
 
Q23 Would you talk to a genetic counselor or physician about your testing results?  
o Yes, I already have  
o Yes, if I found something that concerned me  
o Maybe  




Q24 Please rate your level of regret to being genetically tested. 
o 0  
o 1  
o 2  
o 3  
o 4  
o 5  
o 6   
o 7   
o 8   
o 9   
o 10  
Q25 Which of the following reasons, if any, apply to why you participated or considered 
participating in genetic testing? Please select all that apply. 
▢ I wanted to know if I was at risk for a certain disease   
▢ I wanted to contribute my data to scientific research  
▢ I wanted to test my sensitivity to certain medications  
▢ I wanted to find out about my genetic ancestry  
▢ I wanted to know my carrier status for different disorders  
▢ I wanted to find out more about my genetic traits  
▢ I was curious about how genetic testing works  
▢ I am interested in genetics in general  
▢ I took the test for fun  
▢ A healthcare professional advised the test   
▢ My family wanted me to take the test  
▢ The test was available to me for free   
▢ I wanted to find relatives  




Q26 When considering genetic testing, which of the following is/were a barrier to being 
tested? Please select all that apply. 
▢ I was worried about the results of the test  
▢ I did not think the results were valid  
▢ I did not think the results were useful  
▢ I was concerned about the privacy of my data  
▢ I was skeptical of genetic testing in general 
▢ I was concerned about the cost of genetic testing  
▢ I was concerned about the time involved in testing  
▢ I was concerned about the test not being recommended by a healthcare 
professional  
▢ I was not interested in my genetic data  
▢ I was not interested in the genetics at all   
▢ Genetic testing goes against my religion and/or morals  
▢ I was worried about my genetic information being used to discriminate against 
me   
 
Q27 Please rate your confidence in the quality of results DTC genetic testing provides. 
o 0   
o 1   
o 2   
o 3   
o 4   
o 5   
o 6   
o 7   
o 8  
o 9  




Q28 Please rate your confidence in the accuracy of the results DTC genetic testing 
provides.  
o 0  
o 1  
o 2  
o 3  
o 4  
o 5  
o 6  
o 7   
o 8   
o 9   
o 10  
 
Q29 Please rate your opinion on the cost of genetic testing. 
o 0   
o 1   
o 2   
o 3   
o 4   
o 5   
o 6   
o 7   
o 8   
o 9   
o 10   







Appendix 2: IRB Approval Form 
 
 
Office of Research Integrity 
Institutional Review Board (IRB) 
2000 University Avenue 





DATE: February 25, 2020 
TO: Taylor Johnson 
FROM: Ball State University IRB 
RE: IRB protocol # 1525218-1 
TITLE: Perceptions of College Students on Direct-to-Consumer Genetic Testing 
SUBMISSION TYPE: New Project 
 
DECISION: APPROVED 
PROJECT STATUS: EXEMPT 
DECISION DATE: February 25, 2020 
REVIEW TYPE: Exempt Review 
 
The designated reviewer for the Institutional Review Board (IRB) reviewed your protocol and 
determined the procedures you have proposed are appropriate for exemption under the federal 
regulations. As such, there will be no further review of your protocol, and you are cleared to proceed 
with the procedures outlined in your protocol. As an exempt study, there is no requirement for 
continuing review. Your protocol will remain on file with the IRB as a matter of record. All research 
under this protocol must be conducted in accordance with the approved submission and in accordance 




 Category 1: Research conducted in established or commonly accepted educational settings, 
that specifically involves normal educations practices that are not likely to adversely impact 
students' opportunity to learn required educational content or the assessment of educators 
who provide instruction. This includes most research on regular and special education 
instructional strategies, and research on the effectiveness of or the comparison among 




Category 2: Research that only includes interactions involving educational test (cognitive, 
diagnostic, aptitude, achievement), survey procedures, interview procedures, or observation 
of public behavior (including visual or auditory recording) if at least one of the following 
criteria is met: (i) The information obtained is recorded by the investigator in such a manner 
that the identity of the human subjects cannot readily be ascertained, directly or through 
identifiers linked to the subjects; (ii) Any disclosure of the human subjects' responses outside 
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 the research would not reasonably place the subjects at risk of criminal or civil liability or be 
damaging to the subjects' financial standing, employability, educational advancement, or 
reputation; or (iii) The information obtained is recorded by the investigator in such a manner 
that the identity of the humans subjects can readily be ascertained, directly or through 
identifiers linked to the subjects, and an IRB conducts a limited IRB review to make the 
determination required by 46.111(a)(7). 
 Category 3: Research involving benign behavioral interventions in conjunction with the 
collection of information from an adult subject through verbal or written responses (including 
data entry) or audiovisual recording if the subject prospectively agrees to the intervention 
and information collection and at least one of the following criteria is met: (A) The information 
obtained is recorded by the investigator in such a manner that the identity of human subjects 
cannot be readily ascertained, directly or through identifiers linked to the subjects; (B) Any 
disclosure of the human subjects' responses outside the research would not reasonably 
place the subjects at risk of criminal or civil liability or be damaging to the subjects' financial 
standing, employability, educational advancement, or reputation; or (C) The information 
obtained is recorded by the investigator in such a manner that the identity of the human 
subjects can be readily ascertained, directly or through identifiers linked to the subjects, and 
an IRB conducts a limited IRB review to make the determination required by 46.111(a)(7). 
 Category 4: Secondary research for which consent is not required. 
 Category 5: Research and demonstration projects that are conducted or supported by a 
Federal department or agency, or otherwise subject to the approval of department or agency 
heads, and that are designed to study, evaluate, improve, or otherwise examine public benefit 
or service programs, including procedures for obtaining benefits or services under those 
programs, possible changes in or alternatives to those programs or procedures, or possible 
changes in methods or levels of payment for benefits or services under those programs. 
 Category 6: Taste and food quality evaluation and consumer acceptance studies, (i) if 
wholesome foods without additives are consumed or (ii) if a food is consumed that contains a 
food ingredient at or below the level found to be safe, by the Food and Drug Administration or 
approved by the Environmental Protection Agency or the Food Safety and Inspection Service 
of the U.S. Department of Agriculture. 
 Category 7: Storage or maintenance for secondary research for which broad consent 
is required: Storage or maintenance of identifiable private information or identifiable 
biospecimens for potential secondary research use if an IRB conducts a limited IRB review 
and makes the determinations required by 46.111(a)(8). 
 Category 8: Secondary research for which broad consent is required: Research involving 
the use of identifiable private information or identifiable biospecimens for secondary research 
use, if the following criteria are met: (1)Broad consent for the storage, maintenance, and 
secondary research use of the identifiable private information or identifiable biospecimens 
was obtained in accordance with §46.116(a)(1) through (4), (a)(6), and (d); (2) Documentation 
of informed consent or waiver of documentation of consent was obtained in accordance with 
§46.117; and (3) An IRB conducts a limited IRB review and makes the determination required 
by §46.111(a)(7) and makes the determination that the research to be conducted is within 
the scope of the broad consent referenced in paragraph (d)(8)(i) of this section; and (iv) The 
investigator does not include returning individual research results to participants as part of the 
study plan. Note: This provision does not prevent an investigator from abiding by any legal 
requirements to return individual research results. 
Ball State Specific Exempt Categories 
 Category 9: Research involving publicly observable online behavior. Any online behavior 
that requires a person's permission to access is considered private and does not fall under 




 Category 10: Research involving BSU students who are under 18 but have legal authority 
over their FERPA protected information. Only studies that fall into another exempt category 








While your project does not require continuing review, it is the responsibility of the P.I. (and, if 
applicable, faculty supervisor) to inform the IRB if the procedures presented in this protocol are to be 
modified or if problems related to human research participants arise in connection with this project. 
Any procedural modifications must be evaluated by the IRB before being implemented, as 
some modifications may change the review status of this project. Please contact Sena Lim at 
(765)285-5034 or slim2@bsu.edu if you are unsure whether your proposed modification requires 
review or have any questions. Proposed modifications should be addressed in writing and submitted 
electronically to the IRBNet as a "Modification/Amendment" for review. Please reference your IRB 
protocol number 1525218-1 in any communication to the IRB regarding this project. 
 
In the case of an adverse event and/or unanticipated problem, you will need to submit written 
documentation of the event to IRBNet under this protocol number and you will need to directly notify 
the Office of Research Integrity (http://www.bsu.edu/irb) within 5 business days. If you have 
questions, please contact Sena Lim at (765)285-5034 or slim2@bsu.edu. 
 
Reminder: Even though your study is exempt from the relevant federal regulations of the Common Rule 
(45 CFR 46, subpart A), Ball State has elected to hold you accountable to these regulations to 
encourage best research practices. You and your research team are not exempt from ethical research 
practices and should therefore employ all protections for your participants and their data which are 
appropriate to your project. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
